JOHN M DAGLE, MD
Medical Practice at Hawkins Dr, Iowa City, IA
License number
Iowa 30414
Category
Medical Practice
Type
Neonatal-Perinatal Medicine
Address
Address
200 Hawkins Dr, Iowa City, IA 52242
Phone
(319) 353-7009
(319) 356-4685 (Fax)
(319) 356-4685 (Fax)
Organization information
See more information about JOHN M DAGLE at bizstanding.comUniversity Of Iowa Health Care - John M Dagle MD
200 Hawkins Dr #4802, Iowa City, IA 52242
Categories:
Pediatrics Physicians & Surgeons
Phone:
(319) 353-7009 (Phone)
Professional information
Dr. John M Dagle, Iowa City IA - MD (Doctor of Medicine)
Specialties:
Neonatal Medicine
Address:
200 Hawkins Dr, Iowa City 52242
(319) 353-7009 (Phone), (319) 356-4685 (Fax)
UNIVERSITY OF IOWA HOSPITALS AND CLINICS
200 Hawkins Dr, Iowa City 52242
(319) 356-1616 (Phone), (319) 356-7533 (Fax)
(319) 353-7009 (Phone), (319) 356-4685 (Fax)
UNIVERSITY OF IOWA HOSPITALS AND CLINICS
200 Hawkins Dr, Iowa City 52242
(319) 356-1616 (Phone), (319) 356-7533 (Fax)
Certifications:
Pediatrics, 1995, Perinatal Medicine & Neonatal Medicine, 1999
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
200 Hawkins Dr, Iowa City 52242
UNIVERSITY OF IOWA HOSPITALS AND CLINICS
200 Hawkins Dr, Iowa City 52242
University of Iowa Hospital and Clinics
200 Hawkins Dr, Iowa City 52242
UNIVERSITY OF IOWA HOSPITALS AND CLINICS
200 Hawkins Dr, Iowa City 52242
University of Iowa Hospital and Clinics
200 Hawkins Dr, Iowa City 52242
Education:
Medical School
University of Ia Roy J & L Carver Com
Graduated: 1991
University Iowa Hosps and Clinics
University of Ia Roy J & L Carver Com
Graduated: 1991
University Iowa Hosps and Clinics
John M Dagle, Iowa City IA
Specialties:
Pediatrician
Address:
200 Hawkins Dr, Iowa City, IA 52242
Education:
Doctor of Medicine
Board certifications:
American Board of Pediatrics Sub-certificate in Neonatal-Perinatal Medicine (Pediatrics)
Dna Molecules Stabilized By Modifications Of The 3'-Terminal Phosphodiester Linkage
US Patent:
6197944, Mar 6, 2001
Filed:
Jun 29, 1994
Appl. No.:
8/268381
Inventors:
Joseph A. Walder - Iowa City IA
Roxanne Y. Walder - Iowa City IA
Paul S. Eder - Iowa City IA
John M. Dagle - Iowa City IA
Roxanne Y. Walder - Iowa City IA
Paul S. Eder - Iowa City IA
John M. Dagle - Iowa City IA
Assignee:
Integrated DNA Technologies, Inc. - Coralville IA
International Classification:
C07H 1900
US Classification:
536 221
Abstract:
The use of oligodeoxynucleotides modified at the 3'-terminal internucleotide link as therapeutic agents by a method of hybridizing the modified oligonucleotide to a complementary sequence within a targeted mRNA and cleaving the mRNA within the RNA-DNA helix by the enzyme RNaseH to block the expression of the corresponding gene.
Methods For Decreasing The Expression Of Specifically Targeted Genes
US Patent:
5962425, Oct 5, 1999
Filed:
Jun 2, 1995
Appl. No.:
8/460704
Inventors:
Joseph A. Walder - Iowa City IA
Roxanne Y. Walder - Iowa City IA
Paul S. Eder - Iowa City IA
John M. Dagle - Iowa City IA
Roxanne Y. Walder - Iowa City IA
Paul S. Eder - Iowa City IA
John M. Dagle - Iowa City IA
Assignee:
University of Iowa Research Foundation - Iowa City IA
International Classification:
A61K 4800
US Classification:
514 44
Abstract:
The use of oligodeoxynucleotides modified at the 3'-terminal internucleotide link as therapeutic agents by a method of hybridizing the modified oligonucleotide to a complementary sequence within a targeted mRNA and cleaving the mRNA within the RNA-DNA helix by the enzyme RNaseH to block the expression of the corresponding gene.
Positively Charged Oligonucleotides As Regulators Of Gene Expression
US Patent:
6331617, Dec 18, 2001
Filed:
Mar 27, 1998
Appl. No.:
9/049277
Inventors:
Daniel L. Weeks - Iowa City IA
John Dagle - Iowa City IA
John Dagle - Iowa City IA
Assignee:
University of Iowa Research Foundation - Iowa City IA
International Classification:
C07H 2104, C07H 1900, A01N 4304
US Classification:
536 245
Abstract:
This invention relates to oligonucleotides with cationic phosphoramidate internucleoside linkages useful for binding to nucleic acid to inhibit or alter gene expression.
Oligonucleotides With Cationic Phosphoramidate Internucleoside Linkages And Methods Of Use
US Patent:
6274313, Aug 14, 2001
Filed:
Mar 27, 1998
Appl. No.:
9/049726
Inventors:
Daniel L. Weeks - Iowa City IA
John Dagle - Iowa City IA
John G. K. Williams - Ankeny IA
John Dagle - Iowa City IA
John G. K. Williams - Ankeny IA
Assignee:
Pioneer-Hybrid International, Inc. - Johnston IA
University of Iowa Research Foundation - Iowa City IA
University of Iowa Research Foundation - Iowa City IA
International Classification:
C12Q 168, C12P 1934, C07H 2104, C07H 2102
US Classification:
435 6
Abstract:
This invention relates to the use of oligonucleotides with cationic phosphoramidate internucleoside linkages for the identification of nucleic acid under DNA--DNA duplex denaturing conditions.
Methods For Blocking The Expression Of Specifically Targeted Genes
US Patent:
5491133, Feb 13, 1996
Filed:
Mar 19, 1991
Appl. No.:
7/672088
Inventors:
Joseph A. Walder - Iowa City IA
Roxanne Y. Walder - Iowa City IA
Paul S. Eder - Iowa City IA
John M. Dagle - Iowa City IA
Roxanne Y. Walder - Iowa City IA
Paul S. Eder - Iowa City IA
John M. Dagle - Iowa City IA
Assignee:
University of Iowa Research Foundation - Iowa City IA
International Classification:
A01N 4334, C07H 1512, A61K 31395
US Classification:
514 44
Abstract:
The use of oligodeoxynucleotides modified at the 3'-terminal internucleotide link as therapeutic agents by a method of hybridizing the modified oligonucleotide to a complementary sequence within a targeted mRNA and cleaving the mRNA within the RNA-DNA helix by the enzyme RNaseH to block the expression of the corresponding gene.
Positively Charged Oligonucleotides As Regulators Of Gene Expression
US Patent:
5734040, Mar 31, 1998
Filed:
Mar 21, 1996
Appl. No.:
8/619301
Inventors:
Daniel L. Weeks - Iowa City IA
John Dagle - Iowa City IA
John Dagle - Iowa City IA
Assignee:
University of Iowa Research Foundation - Iowa City IA
International Classification:
C07H 2104, C12N 1585
US Classification:
536 245
Abstract:
This invention relates to oligonucleotides with ethylenediamine phosphoramidate internucleoside linkages useful for binding to eukaryotic duplex DNA to inhibit or alter gene expression.